Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.

De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA.

Am J Clin Pathol. 2009 May;131(5):694-700. doi: 10.1309/AJCPBS85VJEOBPDO.

PMID:
19369630
2.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

3.

Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.

Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi K, Seto T, Takenoyama M, Ichinose Y, Sugio K.

Surg Today. 2016 Sep;46(9):1091-8. doi: 10.1007/s00595-015-1295-z. Epub 2015 Dec 28.

PMID:
26711128
4.

Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.

Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A.

Virchows Arch. 2006 Jun;448(6):788-96. Epub 2006 Apr 6.

PMID:
16598499
5.

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ.

J Mol Diagn. 2007 Jul;9(3):320-6.

6.

Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.

Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ.

Int J Oncol. 2012 Jun;40(6):1900-6. doi: 10.3892/ijo.2012.1396. Epub 2012 Mar 7.

PMID:
22407457
7.

The histopathology of BRAF-V600E-mutated lung adenocarcinoma.

Yousem SA, Nikiforova M, Nikiforov Y.

Am J Surg Pathol. 2008 Sep;32(9):1317-21. doi: 10.1097/PAS.0b013e31816597ca.

PMID:
18636014
8.

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD.

Am J Surg Pathol. 2008 Jun;32(6):810-27. doi: 10.1097/PAS.0b013e31815cb162.

PMID:
18391747
9.

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH.

Virchows Arch. 2005 May;446(5):483-8. Epub 2005 Apr 7.

PMID:
15815931
10.

Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.

Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL, Date H.

Anticancer Res. 2011 Dec;31(12):4619-23.

PMID:
22199339
11.

Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.

Sousa V, Rodrigues C, Silva M, Alarcão AM, Carvalho L.

Rev Port Pneumol (2006). 2015 May-Jun;21(3):113-25. doi: 10.1016/j.rppnen.2014.09.009. Epub 2015 Mar 11.

PMID:
25926253
12.

BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.

Jakubowski M, Hunt JL.

Am J Surg Pathol. 2009 Nov;33(11):1590-3. doi: 10.1097/PAS.0b013e3181b7c7ae.

PMID:
19738460
13.

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF.

Cancer Res. 2005 Mar 1;65(5):1642-6.

14.

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ.

J Clin Oncol. 2011 May 20;29(15):2046-51. doi: 10.1200/JCO.2010.33.1280. Epub 2011 Apr 11.

15.

Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.

Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF, Shimizu N.

Cancer Res. 2006 Feb 1;66(3):1371-5.

16.

Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis.

Zhang J, Liang Z, Gao J, Luo Y, Liu T.

Histopathology. 2011 Dec;59(6):1204-14. doi: 10.1111/j.1365-2559.2011.04050.x.

PMID:
22175900
17.

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.

Mayr D, Hirschmann A, Löhrs U, Diebold J.

Gynecol Oncol. 2006 Dec;103(3):883-7. Epub 2006 Jun 30.

PMID:
16806438
18.

A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.

Sartori G, Cavazza A, Bertolini F, Longo L, Marchioni A, Costantini M, Barbieri F, Migaldi M, Rossi G.

Am J Clin Pathol. 2008 Feb;129(2):202-10. doi: 10.1309/THU13F3JRJVWLM30.

PMID:
18208799
19.

Uncommon V599E BRAF mutations in Japanese patients with lung cancer.

Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

J Surg Res. 2006 Jun 15;133(2):203-6. Epub 2005 Dec 27.

PMID:
16376942
20.

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.

Clin Cancer Res. 2006 Jan 1;12(1):57-61.

Supplemental Content

Support Center